Table 5.
Association between CA 15–3 velocity, CEA velocity, either CA 15–3 or CEA velocity and cancer recurrence after adjusting for tumour clinicopathological characteristics.
| Recurrence |
Unadjusted |
Adjusted |
||||
|---|---|---|---|---|---|---|
| No (%) | Yes (%) | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| CA 15–3 velocity | ||||||
| <=2.5U/mL/year | 55 (87.3) | 8 (12.7) | REF | P<0.001 | ||
| >2.5U/mL/year | 12 (16.9) | 59 (83.1) | 33.8 (12.9, 88.9) | |||
| CEA velocity | ||||||
| <=1.2ng/mL/year | 57 (78.1) | 16 (21.9) | REF | P<0.001 | ||
| >1.2ng/mL/year | 10 (18.2) | 45 (81.8) | 16.0 (6.6, 38.7) | |||
| Combined criteria either CA 15–3 or CEA velocity | ||||||
| CA 15–3 ≤ 2.5 & CEA ≤ 1.2 | 49 (92.5) | 4 (7.5) | REF | P < 0.001 | REF | P < 0.001 |
| CA 15–3 >2.5 or CEA >1.2 | 18 (22.2) | 63 (77.8) | 42.9 (13.6, 134.9) | 73.4 (12.0, 448.6) | ||